Professor S.R. Bloom
　

　* Chairman, Society for Endocrinology

　* Vice President, Royal College of Physicians

　* Chairman， Medical Research Society

　* British Diabetic Association Research Committee

　* Committee on Safety of Medicines sub-committee on biologicals

　* MRC, Physiological Medicine and Infections Board, Grants Committee A

　* National Institute Biological Standards Board

　* National Institute Biological Standards Scientific Committee

　* Chairman – Bayliss & Starling Society

　* Honorary president of Beijing Chaoyang Diabetes Hospital

Member of Scientific Board of AstraZenica 2001 ─ 2003. Assessor, Upjohn, Kalamazoo, 1975-1985. External Metabolic Advisory Board, Novartis, 1991 ─ 1995. SAB member Argeta, Alanex, Alizyme. Metabolic Consultant Roche, Pfizer, Merck, GSK and J & J.

Professor S.R. Bloom is the Chief of Service for Metabolic Medicine (fused Clinical Chemistry and Endocrinology services). He directs a unique international assay service, set up over twenty years ago, to diagnose endocrine tumours. He is a Clinical Director of Pathology for Hammersmith Hospitals Trust, where it was instigated to take over of the pathology services of West Middlesex Hospital and Ealing Hospital . This five- hospital service has an annual budget of ￡ 28M.

Professor S.R. Bloom has also contributed to teaching work. He has 61 PhD and MD students personally supervised (all successful). He is a Senior Membership Examiner Royal College of Physicians(MRCP) from 1987 to 2001 (Senior Censor). He participated fully in departmental undergraduate and postgraduate teaching programme and more latterly in the reorientation of the Faculty undergraduate pathology programme. For ten years He has ran an annual nine month Diploma in Endocrinology course.

Professor S.R. Bloom has made a great deal in research work. The general theme is the pathophysiology of peptide control of the endocrine system, focusing on hypothalamus, pituitary and islet. This addresses the disease areas of obesity and diabetes.

For example, the message for a new major pituitary and hypothalamic neurotransmitter, Neuromedin U, has been cloned and other family members identified. The pathophysiology of this peptide and its flanking peptides are now being established. A new highly potent pituitary and islet peptide, Kisspeptin, is the subject of an active programme to identify its mRNA, pathophysilolgyand post receptor action.

The general theme of demonstrating the importance of peptide mediators is focusing on mechanisns regulating appitite and energy expenditure. We have demonstrated that loss of appetite after eating a meal is consequent on release from the gut of specific peptide hormones (ghrelin, PP. GLP1, oxyntomodulin and PYY). These offer considerable promise as practical agents to control appetite in man.